Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245671 | 1.00 | ALDH1A1 (0.46) | ALDH1A1IDO1TDO2IDO2CYP3A4 | |
| SCHEMBL30029908 | 0.77 | ALDH1A1 (0.49) | ALDH1A1IDO1TDO2IDO2CYP3A4 | |
| SCHEMBL8660409 | 0.77 | ALDH1A1 (0.49) | ALDH1A1IDO1TDO2IDO2CYP3A4 | |
| SCHEMBL8830287 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CYP1A2CYP2D6NFKB1 | |
| SCHEMBL9664891 | 0.77 | ALDH1A1 (0.62) | ALDH1A1IDO1TDO2IDO2CYP3A4 | |
| SCHEMBL28847192 | 0.76 | MAP2K1 (0.40) | ALDH1A1CYP3A4CYP1A2LMNATSHR | |
| Hydrochloric Acid SCHEMBL8918532 | 0.76 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CYP1A2CYP2D6NFKB1 | |
| SCHEMBL1629226 | 0.76 | ALDH1A1 (0.47) | ALDH1A1IDO1TDO2IDO2CYP3A4 | |
| SCHEMBL6778296 | 0.75 | LMNA (0.57) | ALDH1A1IDO1TDO2CYP3A4LMNA | |
| SCHEMBL7868609 | 0.74 | IDO1 (0.40) | ALDH1A1IDO1TDO2CYP3A4DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115888686-B | Cerium oxide@carbon composite material catalyst and synthetic method and application thereof | 安徽师范大学 | 2024-09-24 | — | — | CN | disclosed |
| CN-104326934-A | Preparation method of medical intermediate 2-chlorobenzene glycine methyl hydrochloride | JIANFENG SHEN | 2015-02-04 | — | — | CN | disclosed |
| EP-2168969-A2 | Racemization and Enantiomer Separation of Clopidogrel | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-31 | — | — | EP | disclosed |
| EP-1483269-B1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMA (IL) | 2009-10-14 | — | — | EP | disclosed |
| US-7259261-B2 | Racemization and enantiomer separation of clopidogrel | TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság (HU) | 2007-08-21 | — | — | US | disclosed |
| US-20050049275-A1 | Racemization and enantiomer separation of clopidogrel | ENTIRE INTEREST | 2005-03-03 | — | — | US | disclosed |
| EP-1483269-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | Teva Pharmaceutical Industries Limited (IL) | 2004-12-08 | — | — | EP | disclosed |
| US-6800759-B2 | REACTING MIXTURE OF (R) AND (S) CLOPIDOGREL FREE BASE WITH LEVOROTATORY CAMPHORSULFONIC ACID IN C5 TO C12 HYDROCARBON TO PRECIPITATE (S) CLOPIDOGREL CAMPHORSULFONATE, CONVERTING TO FREE BASE, PRECIPITATING CLOPIDOGREL BISULFATE IN SOLVENT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-05 | — | — | US | disclosed |
| US-6737411-B2 | CRYSTALLIZING AS CAMPHOR SULFONATE SALT; CONVERTING PURIFIED MATERIAL BACK TO FREE BASE FORM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-05-18 | — | — | US | disclosed |
| WO-2004013147-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-02-12 | — | — | WO | disclosed |
| US-20040024012-A1 | Racemization and enantiomer separation of clopidogrel | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-02-05 | — | — | US | disclosed |
| US-20040024011-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMACEUTICALS USA, INC. | 2004-02-05 | — | — | US | disclosed |
| CN-1111162-C | Artemisinin derivatives, method for preparation thereof and pharmaceutical compositions containing the same | SHANGHAI INST OF MATERIAL MEDI (CN) | 2003-06-11 | — | — | CN | disclosed |
| US-6307068-B1 | TREATING OR IN PREVENTING CANCER. | ADIR ET COMPAGNIE (FR) | 2001-10-23 | — | — | US | disclosed |
| CN-1305482-A | Artemisinin derivatives, method for preparation thereof and pharmaceutical compositions containing the same | SHANGHAI INST OF MATERIAL MEDI (CN) | 2001-07-25 | — | — | CN | disclosed |
| EP-1086107-A1 | ARTEMISININ DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065914-A1 | ARTEMISININ DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SHANGHAI INSTITUTE OF MATERIA MEDICA (CN) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024012-A1 | Racemization and enantiomer separation of clopidogrel | SRR, TBXA2R, PTGIR | ALDH1A1 1422/4885IDO1 2530/4885TDO2 303/4885 |
| US-20040024011-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | SRR, TBXA2R, PTGIR | ALDH1A1 1422/4885IDO1 2530/4885TDO2 303/4885 |
| US-20050049275-A1 | Racemization and enantiomer separation of clopidogrel | SRR, TBXA2R, PTGIR | ALDH1A1 1422/4885IDO1 2530/4885TDO2 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.